SpringWorks Therapeutics Target of Unusually Large Options Trading (NASDAQ:SWTX)

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) saw unusually large options trading activity on Monday. Stock investors acquired 5,756 call options on the stock. This is an increase of 721% compared to the typical volume of 701 call options.

Insider Transactions at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, COO Badreddin Edris sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total value of $839,400.00. Following the completion of the transaction, the chief operating officer now directly owns 209,600 shares in the company, valued at $8,796,912. This trade represents a 8.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 7.61% of the company’s stock.

Institutional Investors Weigh In On SpringWorks Therapeutics

Large investors have recently modified their holdings of the business. FMR LLC boosted its position in SpringWorks Therapeutics by 0.3% in the third quarter. FMR LLC now owns 11,140,946 shares of the company’s stock valued at $356,956,000 after buying an additional 28,555 shares in the last quarter. Maverick Capital Ltd. lifted its holdings in SpringWorks Therapeutics by 6.8% in the third quarter. Maverick Capital Ltd. now owns 2,778,348 shares of the company’s stock valued at $89,018,000 after buying an additional 177,824 shares during the period. Geode Capital Management LLC grew its stake in SpringWorks Therapeutics by 7.0% during the third quarter. Geode Capital Management LLC now owns 1,670,247 shares of the company’s stock worth $53,526,000 after purchasing an additional 109,189 shares during the period. Principal Financial Group Inc. lifted its position in shares of SpringWorks Therapeutics by 20.2% during the 4th quarter. Principal Financial Group Inc. now owns 1,103,858 shares of the company’s stock valued at $39,882,000 after acquiring an additional 185,413 shares during the period. Finally, Finepoint Capital LP raised its holdings in shares of SpringWorks Therapeutics by 2.0% during the third quarter. Finepoint Capital LP now owns 650,852 shares of the company’s stock valued at $20,853,000 after purchasing an additional 12,500 shares during the period.

SpringWorks Therapeutics Stock Performance

NASDAQ:SWTX traded up $14.00 during mid-day trading on Monday, reaching $54.28. 6,639,044 shares of the company’s stock were exchanged, compared to its average volume of 1,917,997. SpringWorks Therapeutics has a one year low of $28.21 and a one year high of $55.99. The business’s fifty day simple moving average is $37.86 and its two-hundred day simple moving average is $36.16. The firm has a market capitalization of $4.04 billion, a PE ratio of -14.02 and a beta of 0.81.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.03. The company had revenue of $49.10 million for the quarter, compared to analysts’ expectations of $53.28 million. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The business’s revenue for the quarter was up 4810.0% on a year-over-year basis. During the same period last year, the firm earned ($1.27) earnings per share. As a group, equities research analysts forecast that SpringWorks Therapeutics will post -3.03 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on SWTX shares. Evercore ISI started coverage on shares of SpringWorks Therapeutics in a research report on Wednesday, November 20th. They issued an “outperform” rating and a $60.00 price objective on the stock. Guggenheim lowered their price target on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Wedbush restated an “outperform” rating and set a $77.00 price objective on shares of SpringWorks Therapeutics in a report on Monday, January 13th. Finally, HC Wainwright decreased their target price on SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a research report on Tuesday, November 12th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SpringWorks Therapeutics currently has an average rating of “Buy” and an average price target of $70.00.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.